{
    "clinical_study": {
        "@rank": "134548", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and\n      efficacy of RoActemra/Actemra alone or in combination with non-biologic disease modifying\n      antirheumatic drugs (DMARDs) in rheumatoid arthritis patients with an inadequate response to\n      non-biologic DMARDs"
        }, 
        "brief_title": "The Safety and Efficacy of RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rheumatoid Arthritis Patients.", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients >/= 18 years of age.\n\n          -  Patients with a diagnosis of active RA according to the revised (1987) ACR criteria\n             or EULAR/ACR (2010) criteria.\n\n          -  Oral corticosteroids (</= 10 mg/day prednisone or equivalent), NSAIDs and\n             non-biologic DMARDs are permitted if on a stable dose regimen for >/= 4 weeks prior\n             to Baseline.\n\n          -  Use of effective contraception throughout the study as defined by protocol; female\n             patients of childbearing potential cannot be pregnant.\n\n        Exclusion Criteria:\n\n          -  Presence of clinically significant medical conditions.\n\n          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic\n             ulcerative lower GI disease that might predispose to perforation.\n\n          -  Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other\n             infections.\n\n          -  Any infection requiring hospitalization or treatment with IV antibiotics within 4\n             weeks of Screening or oral antibiotics within 2 weeks of Screening.\n\n          -  Clinically significant findings on lab tests and/or hepatits B or C, or HIV\n             screenings.\n\n          -  Active TB requiring treatment within the previous 3 years.\n\n          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10\n             years, or breast cancer diagnosed within the previous 20 years.\n\n          -  History of alcohol, drug, or chemical abuse within 1 year prior to Screening.\n\n          -  Neuropathies or other conditions that might interfere with pain evaluation.\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to Screening or planned\n             major surgery within 6 months following Baseline.\n\n          -  Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis,\n             mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic\n             involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's\n             syndrome). Secondary Sj\u00f6gren's syndrome with RA is permitted.\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status\n             in-Rheumatoid Arthritis (Appendix 2).\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age\n             of 16.\n\n          -  Prior history of or current inflammatory joint disease other than RA.\n\n          -  Exposure to RoActemra/Actemra (either IV or SC) at any time prior to Baseline.\n\n          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the\n             investigational drug, whichever is longer) of Screening.\n\n          -  Previous treatment with any cell-depleting therapies, including investigational\n             agents or approved therapies, with alkylating agents such as chlorambucil, or with\n             total lymphoid irradiation.\n\n          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.\n\n          -  Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987479", 
            "org_study_id": "ML28702"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "162 mg will be administered once weekly by subcutaneous injection.", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Almelo", 
                        "country": "Netherlands", 
                        "zip": "7609 PP"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1056 AB"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Apeldoorn", 
                        "country": "Netherlands", 
                        "zip": "7334 DZ"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands", 
                        "zip": "4819 EV"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dordrecht", 
                        "country": "Netherlands", 
                        "zip": "3318AT"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9728 MG"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9700RB"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haarlem", 
                        "country": "Netherlands", 
                        "zip": "2035 RC"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heerlen", 
                        "country": "Netherlands", 
                        "zip": "6419 PC"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hoofddorp", 
                        "country": "Netherlands", 
                        "zip": "2134 TM"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6202 ZA"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 CE"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3079 DZ"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schiedam", 
                        "country": "Netherlands", 
                        "zip": "3118 JH"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sneek", 
                        "country": "Netherlands", 
                        "zip": "8601 ZK"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 GA"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multi-center, Open-label Single Arm Phase IIIb Study on Safety and Efficacy of Subcutaneous (SC) Tocilizumab in Monotherapy or in Combination With Methotrexate (MTX) or Other Non-biologic Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients With an Inadequate Response to Non-biologic DMARDs", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28702 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety: Health assessment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety: Assessment of immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy: Change in DAS28-ESR", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Efficacy: ACR/EULAR responses", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Efficacy: Change in disease activity (CDAI/SDAI)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Efficacy: Change in joint swelling/tenderness (SJC/TJC)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}